A novel vaccine against vaginal Chlamydia trachomatis
一种针对阴道沙眼衣原体的新型疫苗
基本信息
- 批准号:8481512
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-05 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:Antibody FormationAntigen-Presenting CellsAntigensBase SequenceCatechinCellsChimera organismChlamydia trachomatisClinical TrialsCommon iliac lymph nodeDataDevelopmentDoseDrug FormulationsEctopic PregnancyEpithelial CellsFlavonoidsHIVHIV-1HomingHumanImmuneImmune responseImmunityImmunizationIndividualInfectionInfertilityLaboratoriesLeadLifeLymphocyte antigenMeasuresMediatingMedicalMembraneMethodsModelingMorbidity - disease rateMucous MembraneMusMustardOilsPelvic Inflammatory DiseasePhasePopulationPositioning AttributePreparationPublishingRegimenResearchRiskRouteSafetySamplingScheduleSeedsSequence HomologySerumSexually Transmitted DiseasesSmall Business Technology Transfer ResearchSpleenSystemTestingVaccinatedVaccinationVaccine DesignVaccinesVaginaVitamin AVitamin Ebasechronic pelvic paincostcytokinedesigngranzyme Bhigh riskimmunogenicityimprovedmeetingsnovelnovel vaccinespreventprotective efficacyresponsesuccesstransmission processvaccine candidatevaginal transmission
项目摘要
DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. Despite decades of efforts, no vaccine is currently available. The ability to generate a useful vaccine has been limited by 1) the lack of an effective method to deliver antigens that will elicit protective humeral and cell-mediated responses, and 2) the identification of specific antigenic sequences that would protect individuals from the Ct strains that cause sexually transmitted diseases (STD). The proprietary nutritive immune-enhancing delivery system (NIDS) developed by EpitoGenesis, Inc. and the broad-based sequence assessment performed by the Dean lab, in addition to the exciting preliminary data on an Ct and HIV-1 vaccine constructs, provide a unique opportunity to finally obtain an efficacious vaccine that can protect against vaginal transmission of Ct through the use of the novel antigenic constructs formulated with the novel, safe and effective NIDS for mucosal and systemic vaccinations. Furthermore, combinations of mucosal and systemic vaccination routes, lack of sequence homology to human antigens, and promising preliminary results from both EpitoGenesis and the Dean lab warrant a novel vaccine design and vaccination approach that hold promise of success.
描述(由申请人提供):预防沙眼衣原体 (Ct) 感染是一项未得到满足的关键医疗需求。开发有效的疫苗不仅可以减少与这些感染相关的发病率,包括盆腔炎性疾病(PID)、不孕不育、慢性盆腔疼痛和宫外孕,还可以减少包括艾滋病毒传播在内的附带风险。尽管经过数十年的努力,目前仍没有疫苗可用。生产有用疫苗的能力受到以下因素的限制:1) 缺乏有效的方法来传递抗原,从而引发保护性肱骨和细胞介导的反应;2) 无法识别出可以保护个体免受 Ct 毒株感染的特定抗原序列导致性传播疾病 (STD) 的疾病。 EpitoGenesis, Inc. 开发的专有营养免疫增强递送系统 (NIDS) 和 Dean 实验室进行的广泛序列评估,以及有关 Ct 和 HIV-1 疫苗结构的令人兴奋的初步数据,提供了独特的通过使用由新型、安全和有效的 NIDS 配制的新型抗原构建体进行粘膜和全身疫苗接种,最终获得一种有效的疫苗,可以防止 Ct 的阴道传播。此外,粘膜和全身疫苗接种途径的结合、与人类抗原缺乏序列同源性以及 EpitoGenesis 和 Dean 实验室的有希望的初步结果保证了一种新的疫苗设计和疫苗接种方法,有望取得成功。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEBORAH Anne DEAN其他文献
DEBORAH Anne DEAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEBORAH Anne DEAN', 18)}}的其他基金
Impact of ocular microbiome, immune response and Chlamydiae on trachoma following MDA
MDA 后眼部微生物群、免疫反应和衣原体对沙眼的影响
- 批准号:
10646357 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Impact of ocular microbiome, immune response and Chlamydiae on trachoma following MDA
MDA 后眼部微生物组、免疫反应和衣原体对沙眼的影响
- 批准号:
10519058 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Natural History of C. trachomatis urogenital and rectal infections
沙眼衣原体泌尿生殖道和直肠感染的自然史
- 批准号:
10580821 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Natural History of C. trachomatis urogenital and rectal infections
沙眼衣原体泌尿生殖道和直肠感染的自然史
- 批准号:
10356116 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Low-Cost Instrument-free Point-of-Care Test for Chlamydia and Gonorrhea
低成本、免仪器的衣原体和淋病即时检测
- 批准号:
10374833 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Low-Cost Instrument-free Point-of-Care Diagnostic for Neisseria gonorrhoeae
低成本、免仪器的淋病奈瑟氏菌即时诊断
- 批准号:
9256272 - 财政年份:2017
- 资助金额:
$ 30万 - 项目类别:
Low-Cost Instrument-free Point-of-care Platform for Multiplexed Chlamydia Diagnostics
用于多重衣原体诊断的低成本无仪器即时护理平台
- 批准号:
9202973 - 财政年份:2014
- 资助金额:
$ 30万 - 项目类别:
Low-Cost Instrument-free Point-of-care Platform for Multiplexed Chlamydia Diagnos
用于多重衣原体诊断的低成本无仪器即时护理平台
- 批准号:
8782420 - 财政年份:2014
- 资助金额:
$ 30万 - 项目类别:
Low-Cost Instrument-free Point-of-care Platform for Multiplexed Chlamydia Diagnostics
用于多重衣原体诊断的低成本无仪器即时护理平台
- 批准号:
9302265 - 财政年份:2014
- 资助金额:
$ 30万 - 项目类别:
Multiplex diagnostic for biothreat C. psittaci & non-threat respiratory pathogens
生物威胁鹦鹉热衣原体的多重诊断
- 批准号:
8481514 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
相似国自然基金
基于DNA自组装技术的人工抗原呈递细胞设计构建及其免疫功能评价
- 批准号:21907073
- 批准年份:2019
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
具有温度/pH双重响应和甘露糖受体靶向功能的微凝胶疫苗
- 批准号:51903233
- 批准年份:2019
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
高同型半胱氨酸血症放大高脂引起动脉粥样硬化早期发病--管周脂肪的抗原呈递作用
- 批准号:91439206
- 批准年份:2014
- 资助金额:270.0 万元
- 项目类别:重大研究计划
内淋巴囊上皮细胞在内耳免疫调控作用中的分子机制研究
- 批准号:81371084
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
基于抗原呈递细胞表型变化的I型糖尿病特异性防治研究
- 批准号:30571732
- 批准年份:2005
- 资助金额:25.0 万元
- 项目类别:面上项目
相似海外基金
Mechanism of immune response to muscle-directed AAV gene transfer
肌肉定向 AAV 基因转移的免疫反应机制
- 批准号:
10717750 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Characterizing antibody responses to HIV-1 vaccination in next-generation immune humanized mice
表征下一代免疫人源化小鼠对 HIV-1 疫苗接种的抗体反应
- 批准号:
10673292 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Optimization of a Self-Adjuvanting Particle System for Delivering Respiratory Syncytial Virus Prefusion Protein
用于输送呼吸道合胞病毒预融合蛋白的自我辅助颗粒系统的优化
- 批准号:
10666079 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 3
红细胞输注同种免疫的基本和转化机制。
- 批准号:
10711670 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Improving phage-based medicine with immunoengineering
通过免疫工程改进基于噬菌体的医学
- 批准号:
10572011 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别: